|
|
||||||||
k Hel*



*
Basic Research Laboratory and
Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892;
Emory University Vaccine Center at Yerkes, Atlanta, GA 30329;
Wisconsin Regional Primate Research Center, Madison, WI 53715;
¶ National Cancer Institute, Frederick, MD 21702; and
||
Aventis-Pasteur, Toronto, Ontario, Canada
T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8+ and CD4+ T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4+ and CD8+ T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where priming with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8+ T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of subdominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.
This article has been cited by other articles:
![]() |
P. Mooij, S. S. Balla-Jhagjhoorsingh, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, S. Heidari, H. Wolf, M.-J. Frachette, K. Bieler, et al. Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens J. Virol., June 1, 2009; 83(11): 5881 - 5889. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mooij, S. S. Balla-Jhagjhoorsingh, G. Koopman, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, I. Kondova, R. Wagner, H. Wolf, et al. Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates J. Virol., March 15, 2008; 82(6): 2975 - 2988. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-P. Sekaly The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med., January 21, 2008; 205(1): 7 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Gomez, J. L. Najera, E. Domingo-Gil, L. Ochoa-Callejero, G. Gonzalez-Aseguinolaza, and M. Esteban Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice J. Gen. Virol., September 1, 2007; 88(9): 2473 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Petrovas, D. A. Price, J. Mattapallil, D. R. Ambrozak, C. Geldmacher, V. Cecchinato, M. Vaccari, E. Tryniszewska, E. Gostick, M. Roederer, et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection Blood, August 1, 2007; 110(3): 928 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pal, D. Venzon, S. Santra, V. S. Kalyanaraman, D. C. Montefiori, L. Hocker, L. Hudacik, N. Rose, J. Nacsa, Y. Edghill-Smith, et al. Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels. J. Virol., April 1, 2006; 80(8): 3732 - 3742. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hel, W.-P. Tsai, E. Tryniszewska, J. Nacsa, P. D. Markham, M. G. Lewis, G. N. Pavlakis, B. K. Felber, J. Tartaglia, and G. Franchini Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes J. Immunol., January 1, 2006; 176(1): 85 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vaccari, C. J. Trindade, D. Venzon, M. Zanetti, and G. Franchini Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS J. Immunol., September 15, 2005; 175(6): 3502 - 3507. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rosati, A. von Gegerfelt, P. Roth, C. Alicea, A. Valentin, M. Robert-Guroff, D. Venzon, D. C. Montefiori, P. Markham, B. K. Felber, et al. DNA Vaccines Expressing Different Forms of Simian Immunodeficiency Virus Antigens Decrease Viremia upon SIVmac251 Challenge J. Virol., July 1, 2005; 79(13): 8480 - 8492. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Wille-Reece, C.-y. Wu, B. J. Flynn, R. M. Kedl, and R. A. Seder Immunization with HIV-1 Gag Protein Conjugated to a TLR7/8 Agonist Results in the Generation of HIV-1 Gag-Specific Th1 and CD8+ T Cell Responses J. Immunol., June 15, 2005; 174(12): 7676 - 7683. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nacsa, Y. Edghill-Smith, W.-P. Tsai, D. Venzon, E. Tryniszewska, A. Hryniewicz, M. Moniuszko, A. Kinter, K. A. Smith, and G. Franchini Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251 J. Immunol., February 15, 2005; 174(4): 1913 - 1921. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Devito, B. Zuber, U. Schroder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, and J. Hinkula Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity J. Immunol., December 1, 2004; 173(11): 7078 - 7089. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Garulli, Y. Kawaoka, and M. R. Castrucci Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus J. Virol., January 15, 2004; 78(2): 1020 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moniuszko, C. Brown, R. Pal, E. Tryniszewska, W.-P. Tsai, V. M. Hirsch, and G. Franchini High Frequency of Virus-Specific CD8+ T Cells in the Central Nervous System of Macaques Chronically Infected with Simian Immunodeficiency Virus SIVmac251 J. Virol., November 15, 2003; 77(22): 12346 - 12351. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Mascola, M. G. Lewis, T. C. VanCott, G. Stiegler, H. Katinger, M. Seaman, K. Beaudry, D. H. Barouch, B. Korioth-Schmitz, G. Krivulka, et al. Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies J. Virol., October 1, 2003; 77(19): 10348 - 10356. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tritel, A. M. Stoddard, B. J. Flynn, P. A. Darrah, C.-y. Wu, U. Wille, J. A. Shah, Y. Huang, L. Xu, M. R. Betts, et al. Prime-Boost Vaccination with HIV-1 Gag Protein and Cytosine Phosphate Guanosine Oligodeoxynucleotide, Followed by Adenovirus, Induces Sustained and Robust Humoral and Cellular Immune Responses J. Immunol., September 1, 2003; 171(5): 2538 - 2547. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Malkevitch, L. J. Patterson, K. Aldrich, E. Richardson, W. G. Alvord, and M. Robert-Guroff A Replication Competent Adenovirus 5 Host Range Mutant-Simian Immunodeficiency Virus (SIV) Recombinant Priming/Subunit Protein Boosting Vaccine Regimen Induces Broad, Persistent SIV-Specific Cellular Immunity to Dominant and Subdominant Epitopes in Mamu-A*01 Rhesus Macaques J. Immunol., April 15, 2003; 170(8): 4281 - 4289. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Himoudi, J.-D. Abraham, A. Fournillier, Y. C. Lone, A. Joubert, A. O. De Beeck, D. Freida, F. Lemonnier, M. P. Kieny, and G. Inchauspe Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection J. Virol., November 13, 2002; 76(24): 12735 - 12746. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hel, J. Nacsa, E. Tryniszewska, W.-P. Tsai, R. W. Parks, D. C. Montefiori, B. K. Felber, J. Tartaglia, G. N. Pavlakis, and G. Franchini Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+ and CD8+ T Cell Responses J. Immunol., November 1, 2002; 169(9): 4778 - 4787. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tryniszewska, J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, et al. Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy J. Immunol., November 1, 2002; 169(9): 5347 - 5357. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Stevceva, X. Alvarez, A. A. Lackner, E. Tryniszewska, B. Kelsall, J. Nacsa, J. Tartaglia, W. Strober, and G. Franchini Both Mucosal and Systemic Routes of Immunization with the Live, Attenuated NYVAC/Simian Immunodeficiency Virus SIVgpe Recombinant Vaccine Result in Gag-Specific CD8+ T-Cell Responses in Mucosal Tissues of Macaques J. Virol., October 11, 2002; 76(22): 11659 - 11676. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Santra, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, C. I. Lord, R. Pal, G. Franchini, and N. L. Letvin Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys J. Immunol., February 15, 2002; 168(4): 1847 - 1853. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |